Advertisement
Screener

BIOATLA, INC. (BCAB) Graph

BCAB Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $3.34M; Operating expenses $6.27M; Net income $452.00K.
  • 2026-03-31: Revenue (m); Research and development $4.58M; Operating expenses $9.31M; Net income -$6.34M.
  • 2025-12-31: Revenue (m); Research and development $8.00M*; Operating expenses $11.26M*; Net income (m).
  • 2025-09-30: Revenue (m); Research and development $9.54M; Operating expenses $13.79M; Net income -$15.78M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$3.34M$6.27M$452.00K
2026-03-31(m)$4.58M$9.31M-$6.34M
2025-12-31(m)$8.00M*$11.26M*(m)
2025-09-30(m)$9.54M$13.79M-$15.78M
2025-06-30(m)$13.68M$18.65M-$18.71M
2025-03-31(m)$12.36M$17.61M-$15.33M
2024-09-30(m)$16.39M$22.27M-$10.59M
2024-06-30(m)$16.20M$21.97M-$21.07M
2024-03-31(m)$18.85M$24.46M-$23.23M
2023-09-30$0.00$28.40M$35.02M-$33.33M
2023-06-30$0.00$30.96M$37.20M-$35.75M
2023-03-31$0.00$21.70M$28.93M-$27.46M
2022-09-30$0.00$19.84M$26.18M-$25.78M
2022-06-30$0.00$20.71M$29.05M-$28.91M
2022-03-31$0.00$16.92M$24.35M-$24.25M
2021-09-30(m)$16.55M$23.70M-$22.93M
2021-06-30$300.00K$14.85M$30.71M-$30.38M
2021-03-31(m)$10.42M$18.80M-$18.70M
2020-09-30(m)$4.86M$8.16M-$11.63M
2020-06-30(m)$2.92M$4.71M-$6.22M
2020-03-31(m)$1.66M$1.20M-$1.60M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$7.92M$15.58M-$5.89M
2025-06-30(m)$26.04M$36.26M-$34.05M
2024-06-30(m)$35.05M$46.43M-$44.31M
2023-06-30$0.00$52.66M$66.13M-$63.21M
2022-06-30$0.00$37.63M$53.40M-$53.16M
2021-06-30$300.00K$25.27M$49.51M-$49.08M
2020-12-31(m)(m)(m)-$26.88M
2020-06-30(m)$4.58M$5.91M-$7.83M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$35.58M$50.05M-$49.82M
2024-09-30(m)$51.45M$68.70M-$54.89M
2023-09-30$0.00$81.06M$101.15M-$96.54M
2022-09-30$0.00$57.47M$79.58M-$78.94M
2021-09-30$300.00K$41.83M$73.20M-$72.01M
2020-09-30(m)$9.45M$14.07M-$19.46M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$43.57M$61.30M$0.00$59.60M
2024-12-31(m)$63.09M$84.94M$0.00$69.80M
2023-12-31(m)$103.73M$129.69M$0.00$123.50M
2022-12-31(m)$79.35M$108.14M$0.00-$106.48M
2021-12-31$300.00K$58.27M$96.69M$0.00-$95.40M
2020-12-31(m)$19.93M$30.53M$0.00-$35.85M
2019-12-31(m)$25.92M$33.47M(m)-$29.86M

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXOZYMES INC. (EXOZ)United States$0.058B
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02